US FDA approves IV Nexium for GERD in babies
This article was originally published in Scrip
Executive Summary
The US FDA approved AstraZeneca's intravenous form of Nexium (esomeprazole sodium) for children as young as 1 month for the short-term treatment of gastroesophageal reflux disease (GERD) with erosive esophagitis, or inflammation of the esophagus, when oral therapy is not possible or appropriate – making it the first proton-pump inhibitor approved for children under 12 months.